The purpose of this study is to better understand how microorganisms move through the walls of the intestine and cause a response by the immune system, and how these differences affect lupus (Systemic Lupus Erythematosus, or SLE). The study involves a single visit where blood and saliva samples will be collected, and you will be sent home with a gut permeability test (which involves drinking a liquid and collecting urine samples) and a stool sample collection test that you will collect and mail in yourself.
The purpose of this study is to see if a new drug called CC-220 can be safe and effective to treat patients with Systemic Lupus Erythematosus. CC-220 is an oral medication. The study will last for about one year and will involve 16 study visits. There are two parts to the trial: In the first, patients will be assigned to get either CC-220 at 0.45mg, 0.3mg, 0.15 mg, or placebo (no active study drug). In the second part, all patients who got placebo during the first part will be re-assigned to get CC-220 at either 0.45mg or 0.3mg. The study will be blinded, which means you will not know which medication you are getting during either of the two parts. You will see a Rheumatologist, and give a blood and urine sample at each visit. The data obtained from this study will provide additional information to further assess the benefit and risk profile of CC-220 for the treatment of lupus.
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving a placebo infusion plus standard of care.
The objective of this study is to obtain viable mesenchymal stem cells (MSCs) from umbilical cords in uncomplicated pregnancies. Potential donors will be screened prior to donation of umbilical cords to confirm no prevalent autoimmune disease or other viruses and/or diseases. The overall goal is to obtain MSCs from healthy donors for eventual transfusion into patients for the treatment of autoimmune disease, specifically systemic lupus erythematosus.
Systemic lupus erythematosus (lupus; SLE) and Systemic Sclerosis (scleroderma; SSc) are relatively rare rheumatic diseases that disproportionately impact the African American community, and particularly African American women. The causes of lupus and scleroderma are unknown, but thought to include both genetic and environmental factors. We are enrolling lupus and scleroderma patients, and healthy control subjects. This is not a drug study. The purpose of this study is to better understand the factors that predispose people to develop lupus and scleroderma. Information about medical, social and family history, medications, physical exam findings, and laboratory tests will be collected for analysis. This study will involve approximately 1360 volunteers.